JP2017519768A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519768A5 JP2017519768A5 JP2016573926A JP2016573926A JP2017519768A5 JP 2017519768 A5 JP2017519768 A5 JP 2017519768A5 JP 2016573926 A JP2016573926 A JP 2016573926A JP 2016573926 A JP2016573926 A JP 2016573926A JP 2017519768 A5 JP2017519768 A5 JP 2017519768A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- antibody
- binding fragment
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462014506P | 2014-06-19 | 2014-06-19 | |
| US62/014,506 | 2014-06-19 | ||
| US201562140849P | 2015-03-31 | 2015-03-31 | |
| US62/140,849 | 2015-03-31 | ||
| PCT/US2015/036576 WO2015196011A1 (en) | 2014-06-19 | 2015-06-19 | Treatment of polybacterials infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020209896A Division JP2021063090A (ja) | 2014-06-19 | 2020-12-18 | 多細菌性感染の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519768A JP2017519768A (ja) | 2017-07-20 |
| JP2017519768A5 true JP2017519768A5 (enExample) | 2018-08-09 |
| JP6845016B2 JP6845016B2 (ja) | 2021-03-17 |
Family
ID=54936121
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016573926A Active JP6845016B2 (ja) | 2014-06-19 | 2015-06-19 | 多細菌性感染の治療 |
| JP2020209896A Pending JP2021063090A (ja) | 2014-06-19 | 2020-12-18 | 多細菌性感染の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020209896A Pending JP2021063090A (ja) | 2014-06-19 | 2020-12-18 | 多細菌性感染の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11168132B2 (enExample) |
| EP (1) | EP3157565B1 (enExample) |
| JP (2) | JP6845016B2 (enExample) |
| KR (1) | KR102549870B1 (enExample) |
| CN (1) | CN106456767B (enExample) |
| AU (1) | AU2015276938B2 (enExample) |
| CA (1) | CA2952278A1 (enExample) |
| ES (1) | ES2983252T3 (enExample) |
| SG (2) | SG11201609652RA (enExample) |
| TW (1) | TWI719938B (enExample) |
| WO (1) | WO2015196011A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2838211C (en) | 2011-06-10 | 2023-08-01 | Medimmmune Limited | Anti-pseudomonas psl binding molecules and uses thereof |
| HUE050985T2 (hu) | 2011-11-07 | 2021-01-28 | Medimmune Ltd | Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák |
| KR20150092738A (ko) | 2012-11-06 | 2015-08-13 | 메디뮨 엘엘씨 | 에스.아우레우스 연관 질병의 치료 방법 |
| CN104968797B (zh) * | 2012-11-06 | 2018-11-30 | 米迪缪尼有限公司 | 金黄色葡萄球菌表面决定簇的抗体 |
| EP3383884A4 (en) | 2015-11-30 | 2019-07-31 | Medimmune Limited | PROCESS FOR PREVENTING OR TREATING NOSOCOMIAL PNEUMONIA |
| AU2017261374B2 (en) | 2016-05-05 | 2024-06-20 | Inovio Pharmaceuticals, Inc. | DNA antibody constructs for use against pseudomonas aeruginosa |
| TWI781130B (zh) | 2017-01-03 | 2022-10-21 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| TWI902669B (zh) | 2018-07-24 | 2025-11-01 | 美商麥迪紐有限責任公司 | 抗金黃色葡萄球菌凝集因子a(clfa)之抗體 |
| WO2020076789A2 (en) | 2018-10-09 | 2020-04-16 | Medimmune, Llc | Combinations of anti-staphylococcus aureus antibodies |
| EP3864040A1 (en) | 2018-10-09 | 2021-08-18 | Medimmune, LLC | Antibodies directed against staphylococcus aureus leukotoxins |
| GB201816554D0 (en) | 2018-10-10 | 2018-11-28 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
| GB201816553D0 (en) | 2018-10-10 | 2018-11-28 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
| WO2020172233A1 (en) * | 2019-02-22 | 2020-08-27 | The Trustees Of Columbia University In The City Of New York | Treatment of prostate cancer by androgen ablation and il-8 blockade |
| TW202100549A (zh) * | 2019-03-13 | 2021-01-01 | 美商麥迪紐有限責任公司 | 降低金黃色葡萄球菌在定殖的患者中之感染 |
| CN113966343A (zh) * | 2019-06-11 | 2022-01-21 | 瑞泽恩制药公司 | 结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法 |
| US20220259290A1 (en) * | 2019-07-24 | 2022-08-18 | Japan Science And Technology Agency | Innovative production technique for antibody-enzyme |
| FR3114970B1 (fr) * | 2020-10-08 | 2023-06-30 | Univ Tours | Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires |
| WO2025117765A1 (en) * | 2023-12-01 | 2025-06-05 | University Of Washington | Protective monoclonal antibodies to pseudomonas aeruginosa |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2719397A1 (en) | 2006-06-12 | 2014-04-16 | GlaxoSmithKline Biologicals SA | Use of alpha-toxin for treating and preventing staphylococcus infections |
| JP2013515079A (ja) * | 2009-12-22 | 2013-05-02 | カロバイオス ファーマシューティカルズ インコーポレイティッド | 低レベルの病原性シュードモナス・エルギノーサ（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）感染症を有する患者のスタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）感染症を治療する方法 |
| SG10201913690SA (en) | 2011-02-08 | 2020-03-30 | Medimmune Llc | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
| HUE050985T2 (hu) * | 2011-11-07 | 2021-01-28 | Medimmune Ltd | Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák |
| KR20150092738A (ko) | 2012-11-06 | 2015-08-13 | 메디뮨 엘엘씨 | 에스.아우레우스 연관 질병의 치료 방법 |
| CN104968797B (zh) | 2012-11-06 | 2018-11-30 | 米迪缪尼有限公司 | 金黄色葡萄球菌表面决定簇的抗体 |
| KR20150082367A (ko) * | 2012-11-06 | 2015-07-15 | 메디뮨 엘엘씨 | 항슈도모나스 ｐｓｌ 및 ｐｃｒｖ 결합 분자를 이용한 병용 요법 |
| WO2017075188A2 (en) | 2015-10-30 | 2017-05-04 | Medimmune, Llc | Methods of using anti-alpha toxin antibody |
-
2015
- 2015-06-18 TW TW104119861A patent/TWI719938B/zh active
- 2015-06-19 SG SG11201609652RA patent/SG11201609652RA/en unknown
- 2015-06-19 JP JP2016573926A patent/JP6845016B2/ja active Active
- 2015-06-19 CN CN201580032548.7A patent/CN106456767B/zh active Active
- 2015-06-19 CA CA2952278A patent/CA2952278A1/en active Pending
- 2015-06-19 KR KR1020167034742A patent/KR102549870B1/ko active Active
- 2015-06-19 ES ES15809174T patent/ES2983252T3/es active Active
- 2015-06-19 US US15/319,958 patent/US11168132B2/en active Active
- 2015-06-19 SG SG10201811361XA patent/SG10201811361XA/en unknown
- 2015-06-19 AU AU2015276938A patent/AU2015276938B2/en active Active
- 2015-06-19 WO PCT/US2015/036576 patent/WO2015196011A1/en not_active Ceased
- 2015-06-19 EP EP15809174.4A patent/EP3157565B1/en active Active
-
2020
- 2020-12-18 JP JP2020209896A patent/JP2021063090A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519768A5 (enExample) | ||
| JP2021063090A5 (enExample) | ||
| King | Bronchiectasis | |
| JP6845016B2 (ja) | 多細菌性感染の治療 | |
| DiGiandomenico et al. | Antibacterial monoclonal antibodies: the next generation? | |
| US20240350634A1 (en) | Monoclonal antibody and vaccine targeting filamentous bacteriophage | |
| Sulakvelidze et al. | Bacteriophages as therapeutic agents | |
| JP2016507470A5 (enExample) | ||
| JP2013515079A5 (enExample) | ||
| RU2016116949A (ru) | Анти-лпс о11-антитело | |
| JP2015536951A5 (enExample) | ||
| WO2020201833A8 (en) | Gepotidacin for use in the treatment of bacterial urinary tract infections | |
| JP2012516897A5 (enExample) | ||
| CN111372603A (zh) | 针对铜绿假单胞菌感染的组合物和方法 | |
| JP2008526848A (ja) | 黄色ブドウ球菌感染を治療する方法 | |
| Binar et al. | An unusual cause of necrosis and nasal septum perforation after septoplasty: Enterobacter cloacae | |
| Tur | Clinical Microbiology and Infectious Diseases (ECCMID)-28th European Congress. Madrid, Spain-April 21-24, 2018 | |
| Koff et al. | Clinical use of inhaled bacteriophages to treat multi-drug resistant Pseudomonas aeruginosa | |
| Kim et al. | Infective endocarditis prophylaxis before dental procedures: New guidelines spark controversy | |
| Projan | Antibodies for the Prevention, Treatment, and Preemption of Infectious Diseases | |
| Tümmler | aeruginosa [version 1; peer review: 2 approved] | |
| AI Valasidis et al. | Novel antimicrobial agents for the management of maxillofacial and neck infections | |
| Burkhard | Emerging therapies against infections with Pseudomonas aeruginosa | |
| Popescu et al. | ROLE OF NEW FLUOROQUINOLONES IN THE TREATMENT OF LOWER RESPIRATORY TRACT INFECTIONS | |
| Prucha et al. | 133 Intravenous immunoglobulins in the treatment of autoimmune thrombocytopenia in patients with sepsis |